More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L

The present post hoc analysis of two 30‐week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Main Authors: Frias, Juan, Puig Domingo, Manuel, Meneghini, Luigi, Napoli, Raffaele, Liu, Minzhi, Soltes Rak, Erika, Aroda, Vanita R.
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2018
Assuntos:
Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6099242/
https://ncbi.nlm.nih.gov/pubmed/29785837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13368
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares